Who is sponsoring NCT00941343?

NCT00941343 is sponsored by Sanofi.

What condition does NCT00941343 study?

NCT00941343 studies Prostatic Diseases.

What drugs are being tested in NCT00941343?

Interventions: Alfuzosin (XATRAL® - SL770499).

What is the status of NCT00941343?

NCT00941343 is currently COMPLETED.

Last reviewed 2010-03-29 · How we verify

Sexuality and Management of Benign Prostatic Hyperplasia With Alfuzosin

NCT00941343 NA COMPLETED

Primary Objective: * To assess the sexual function of Benign Prostatic Hyperplasia patients Secondary Objective: * To evaluate the association between Lower Urinary Tract Symptoms severity and sexual disorders * To compare the sexual function, urinary symptoms and Quality of Life of Benign Prostatic Hyperplasia patients on XATRAL 10mg OD among the different regions * To correlate the Male Sexual Health Questionnaire(MSHQ) and 5-item version of the International Index of Erectile Function (IIEF-5) * To assess the onset of action of XATRAL 10mg OD * To assess the peak urinary flow rate * To assess the safety and the tolerability of XATRAL 10mg OD

Details

Lead sponsor	Sanofi
Phase	NA
Status	COMPLETED
Enrolment	362
Start date	2006-09
Completion	2008-09

Conditions

Prostatic Diseases

Interventions

Alfuzosin (XATRAL® - SL770499)

Primary outcomes

Male Sexual Health Questionnaire Ejaculation score (MSHQ) — At week 24

Countries

Taiwan